This case highlights the potential for favorable long-term outcomes in GAD65 antibody-associated encephalitis with appropriate immunotherapy and provides insights into maintenance therapy and medication withdrawal strategies for patients planning pregnancy. This evidence concerns the gene GAD2 and encephalitis.